We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

4 hedge funds and large institutions have $916K invested in VanEck Vectors Generic Drugs ETF in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

0% less capital invested

Capital invested by funds: $920K → $916K (-$4K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NFG
Next Financial Group
Texas
+$7.5K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$26.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$848K -$26.3K -1,050 -3%
IA
2
IFP Advisors
Florida
$55K – – –
NFG
3
Next Financial Group
Texas
$7K +$7.5K +300 New
TRCT
4
Tower Research Capital (TRC)
New York
$6K – – –

GNRX Hedge Fund Activity: Q3 2016 in Review

4 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q3 2016, worth a combined $916K — down 0.43% from $920K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new GNRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Next Financial Group, opening a new position worth an estimated $7.5K. The largest seller was UBS Group, cutting an estimated $26.3K.

  • 4 institutional investors held VanEck Vectors Generic Drugs ETF (GNRX) as of Q3 2016, up from 3 in Q2 2016.
  • Funds reported $916K of VanEck Vectors Generic Drugs ETF stock for Q3 2016, down 0.43% quarter-over-quarter.
  • 1 fund opened new VanEck Vectors Generic Drugs ETF positions in Q3 2016 and 0 closed out, a net change of +1 holder.
  • The largest VanEck Vectors Generic Drugs ETF buyer in Q3 2016 was Next Financial Group, an estimated $7.5K added.
  • The largest VanEck Vectors Generic Drugs ETF seller in Q3 2016 was UBS Group, an estimated $26.3K sold.

Based on aggregated 13F filings for Q3 2016.